Peter Hodson
Medical Facilities Corp.
DR-T
DON'T BUY
Jan 23, 2020
They have surgical facilities in the US. It was trading for the dividend and then things fell off the rails and they cut the dividend. He was concerned that something was wrong. They made an asset sale recently to try to clean things up. Let the shareholder base switch over and let things settle.
A classic avoid stock. The chart has plummeted this year. The trendline (past low) was taken out with several breakdowns and consolidations (several drops).
He owned it because of the big dividend yield. Management was always optimistic about the hospital being built in South Dakota and thought because they had a lot of other facilities it might mitigate the situation. They told us the last two quarters that everything was fine but now we find it is not.
He is always very suspicious of a company with all of its assets in the US that lists on a Canadian exchange. Medical facilities in the US are a different market from the Canadian one. We've seen similar companies in the US where it didn't end well.
It's a real estate play on medical facilities in the US. It was overleveraged a few years ago, then COVID declined their business, which are non-essential surgeries. But they're still profitable and paying dividends. He sees upside.
They own ambulatory facilities in the US. There was concern about how soon they could get their surgeries up and running again after COVID. There are issues around Medicare and Medicaid paying for procedures. These are always a risk. He still owns it. It seems like things are continuing to improve. You could at least get the recovery, although the long term growth is not what it was previously.
Owns it in income growth. Dividend halted with the pandemic. Non-necessary medical procedures were delayed, and now they're coming back rapidly. Dividend will be restored. Stock should at least get north of $10.
They provide elective surgical services in the U.S., though it's a Canadian company. Because of Covid, those services have collapsed, but will recover as the economy reopens. Such surgical demand will be out of sight, because of huge pent-up demand. Also, the valuation is much lower than the historic norm. They will enjoy 2-3 boom years. (Analysts’ price target is $9.84)
(A Top Pick Aug 25/21, Down 14%) It is in the U.S. and has hit 2X Book Value. It is acting like a tech stock but the demand for surgeries is still there. In general the U.S. healthcare business is an expensive market.
Has pulled back a lot. It holds US medical property. It has suffered inflationary pressures, but will diminish in 2023 and the stock will recover. Don't sell it in the current Dutch auction.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.